Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.

NCT05821192 is registered in ClinicalTrials.gov with Ou Bai, MD/PHD as lead sponsor.

NCT NCT05821192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.
Lead sponsor
Ou Bai, MD/PHD
Phase
Not applicable
Overall status
Unknown status
Start date
March 23, 2023
Completion date
December 31, 2024
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma, peripheral t-cell lymphoma, not otherwise specified